Search Videos and More
News
Combination Therapy Produces Encouraging Results in Patients with Gynecologic Cancers with Distinct Genetic Mutations
A two-drug therapy that sets certain cancer cells up for failure and then finishes them off showed encouraging activity in a clinical trial of patients with gynecologic cancers that harbor mutations in a key gene, Dana-Farber investigators reported at the Society for Gynecologic Oncology (SGO) Annual Meeting in March.
Video
Transatlantic Exchanges in Immuno-Oncology
Join our transatlantic panel of experts for an interactive, full-day virtual conference to be up to date with all the most exciting discoveries in immuno-oncology!
News
Newly Identified Regulator in Prostate Cancer Cells Could Serve as Drug Target for Advanced Tumors
Aiming to discover new targets for blocking androgen receptor activity, a Dana-Farber-led team has identified a critical regulator of AR signaling that prostate cancer cells depend on, according to their publication in Cell Reports.
Document
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on August 4, September 3, October 8, 2021, and June 24, 2022 to discuss recommendations for the use of pembrolizumab in patients with early-stage TNBC.
Symposium
Breast Cancer Treatment Guidelines
Following the FDA approval of certain treatments for breast cancer, the faculty in the Breast Oncology Program at Dana-Farber Brigham Cancer Center met to formalize guidelines for how to best utilize the new medications.
Video
Care and Innovation: Medical Oncology at Dana-Farber
Trace the remarkable growth and development of medical oncology at Dana-Farber — from its early roots to today's mission-driven commitment to excellence in research, care, collaboration, and training.
News
Cancer FactFinder Website Launched to Provide Fact-Based, Reliable Information About Causes of Cancer
A team led by the Zhu Family Center for Global Cancer Prevention at Harvard T.H. Chan School of Public Health and the Center for Cancer Equity and Engagement at the Dana-Farber/Harvard Cancer Center has launched a new website that provides accurate and reliable information about what does and does not cause cancer.
Symposium
2022 SGO Highlights
DFCI Faculty share highlights from the Society of Gynecologic Oncology Annual Meeting on Women's Cancers held on March 18-21, 2022, in Phoenix, AZ and online.
News
Dana-Farber Cancer Institute Celebrates 75th Anniversary
Dana-Farber Cancer Institute launched a year-long celebration of its 75th anniversary to highlight its history and progress in cancer care and transformative cancer research. In marking the notable anniversary, Dana-Farber seeks to recognize the Institute’s many scientific discoveries, advancements in cancer care for patients, and its extraordinary contributions to eradicating cancer in both children and adults.
Video
Ursula Matulonis, MD Shares Results of the SORAYA Study
Ursula Matulonis, MD presented results of the SORAYA study at the 2022 Society for Gynecologic Oncology Annual Meeting.
Video
Panos Konstantinopoulos, MD, PhD Shares Results of a Phase 2 Endometrial Cancer Study at 2022 SGO
Panos Konstantinopoulos, MD, PhD shares results of a phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer at the 2022 Society for Gynecologic Oncology Annual Meeting.
News
Lymphoma and Chronic Lymphocytic Leukemia: Updates in Management
This course will address the rapidly changing landscape in the management and treatment of non-Hodgkin lymphoma, Hodgkin Lymphoma, and chronic lymphocytic leukemia